Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2005-05-24
2005-05-24
Woitach, Joseph (Department: 1632)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S069100, C435S325000, C514S04400A
Reexamination Certificate
active
06897057
ABSTRACT:
The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes γ34.5 gene.
REFERENCES:
patent: 5288641 (1994-02-01), Roizman
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5834216 (1998-11-01), Roizman et al.
patent: 5922328 (1999-07-01), Spector et al.
patent: 6120773 (2000-09-01), Roizman
patent: 6172047 (2001-01-01), Roizman et al.
patent: WO 9600007 (1996-01-01), None
patent: WO 9603997 (1996-02-01), None
patent: WO 9704804 (1997-02-01), None
patent: WO9842195 (1998-10-01), None
patent: WO0116331 (2001-03-01), None
Taneja et al., Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells; PNAS; Jul. 17, 2001; vol. 98, No. 15; pp 8804-8808.*
Markovitz et al., The Range and Distribution of Murine Central Nervous System Cells Infected with the Y134.5-Mutant of Herpes Simplex Virus 1; Journal of Virology, Jul. 1997, p. 5560-5569, vol. 71, No. 7.*
Chung et al., B-myb Promoter Retargeting of Herpes Simplex Virus y34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells; Journal of Virology, Sep. 1999, p. 7556-7564.*
Chambers et al., Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma; Proc. Natl. Acad. Sci. USA; vol. 92, pp 1141-1415, Feb. 1995, Medical Sciences.*
Yoon et al., An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma; The FASEB Journal, vol. 14, pp. 201-311.*
Abe, M. and Kufe, D., “Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma-Associated Antigen (MUCl) Gene,”Proc. Natl. Acad. Sci. USA90:282-286 (1993).
Albarracin, C.T., et al., “The Gonadotropin-Releasing Hormone Receptor Gene Promoter Directs Pituitary-Specific Oncogene Expression in Transgenic Mice,”Endocrinology 140:2415-2421 (May 1999).
Amizuka, N., et al., “Vitamin D3 Differentially Regulates Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Expression in Bone and Cartilage,”J. Clin. Invest. 103:373-381 (Feb. 1999).
Andreansky, S.S., et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,”Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).
Arbuthnot, P., et al., “Hepatoma Cell-Specific Expression of a Retrovirally Transferred Gene is Achieved by Alpha-Fetoprotein but not Insulinlike Growth Factor II Regulatory Sequences,”Hepatology 22:1788-1796 (1995).
Bennett, J.D., et al., “E2F Binding is Required but Not Sufficient for Repression of B-mybTranscription in Quiescent Fibroblasts,”Oncogene 13:1073-1082 (1996).
Bischoff, J.R., et al., “An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells,”Science 274:373-376 (1996).
Boviatsis, E.J., et al., “Long-Term Survival of Rats Harboring Brian Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector that Retains an Intact Thymidine Kinase Gene,”Cancer Res. 54:5745-5751 (1994).
Boviatsis, E.J., et al., “Antitumor Activity and Reporter Gene Transfer into Rat Brain Neoplasms Inoculated with Herpes Simplex Virus Vectors Defective in Thymidine Kinase to Ribonucleotide Reductase,”Gene Ther. 1:323-331 (1994).
Burns, J.C., et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,”Proc. Natl. Acad. Sci. USA 90:8033-8037 (1993).
Caruso, M., et al., “Regression of established macroscopic liver metastases after in situ trasnduction of a suicide gene,”Proc. Natl. Acad. Sci. USA90:7024-7028 (1993).
Chambers, R., et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995). (of record).
Chase, M. et al., “An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,”Nature Biotechnol. 16:444-448 (1998).
Chen, S.H., et al., “Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer In Vivo,”Proc. Natl. Acad. Sci. USA 91:3054-3057 (1994).
Chen, L., et al., “Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter,”J. Clin. Invest. 96:2775-2782 (1995).
Chen, L., and Waxman, D.J., “Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,”Cancer Res. 55:581-589 (1995).
Chen, L., et al., “Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene,”Cancer Res. 56:1331-1340 (1996).
Chou, J. and Roizman, B., “The γ1(34.5) Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programed Cell Death in Neuronal Cells,”Proc. Natl. Acad. Sci. USA 89:3266-3270 (1992).
Chou, J., et al., “Association of a Mr90,000 Phosphoprotein with Protein Kinase PKR in Cells Exhibiting Enhanced Phosphorylation of Translation Initiation Factor eIF-2 Alpha and Premature Shutoff of Protein Synthesis After Infection with Gamma 134.5-Mutants of Herpes Simplex Virus 1,”Proc. Natl. Acad. Sci. USA 92:10516-10520 (1995).
Chung, R.Y. and Chiocca, E.A., “Gene Therapy for Tumors of the Central Nervous System,”Surg. Oncol. Clin. N. Am. 7:589-602 (1998).
Clary, B.M., et al., “Transcriptional Targeting for Cancer Gene Therapy,”Surg. Oncol. Clin. N. Am. 7:565-574 (1998).
Coffey, M.C., et al., “Reovirus Therapy of Tumors with Activated Ras Pathway,”Science 282:1332-1334 (1998).
Coll-Fresno, P.M., et al., “Cytotoxic Activity of a Diptheria Toxin/FGF6 Mitotoxin on Human Tumour Cell Lines,”Oncogene 14:243-247 (1997).
Colombo, M.P., et al., “Immunotherapy. I: Cytokine Gene Transfer Strategies,”Cancer Metastasis Rev. 16:421-432 (1997).
Connors, T.A., “The Choice of Prodrugs for Gene Directed Enzyme Prodrug Therapy of Cancer,”Gene Ther. 2:702-709 (1995).
Culver, K.W., “Clinical applications of gene therapy for cancer,”Clin. Chem 40:510-512 (1994).
Dachs, G.U., et al., “Targeting Gene Therapy to Cancer: A Review,”Oncol. Res. 9:313-325 (1997).
Dehal, S.S., et al., “CYP2D6 Catalyzes Tamoxifen 4-hydroxylation in Human Liver,”Cancer Res. 57:3402-3406 (1997).
Deonarain, M.P., et al., “Genetic Delivery of Enzymes for Cancer Therapy,”Gene Therapy 2: 235-244 (1995).
Ezzeddine, Z.D., et al., “Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase gene,”New Biol. 3:608-614 (1991).
Fakhrai, H., et al., “Eradication of Established Intracranial Rat Gliomas by Transforming Growth Factor β Antisense Gene Therapy,”Proc. Natl. Acad. Sci. USA 93:2909-2914 (1996).
Freeman, S.M., et al., “In Situ Use of Suicide Genes for Cancer Therapy,”Semin. Oncol. 23:31-45 (1996).
Freytag, S.O., et al., “A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy,”Hum. Gene Ther. 9:1323-1333 (1998).
Friedlos, F. et al., “Mustard Prodrugs for Activation byEscherichia coliNitroreductase in Gene-Directed Enzyme Prodru
Chiocca E. Antonio
Chung Richard Y.
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
Woitach Joseph
LandOfFree
Cell-specific and/or tumor-specific promoter retargeting of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell-specific and/or tumor-specific promoter retargeting of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-specific and/or tumor-specific promoter retargeting of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435733